MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jstrokecerebrovasdis.2019.02.018

Медицинская библиотека · Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2019

Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage - A Meta-Analysis.

Judge Conor, Ruttledge Sarah, Costello Maria, Murphy Robert, Loughlin Elaine, Alvarez-Iglesias Alberto, Ferguson John, Gorey Sarah, Nolan Aoife, Canavan Michelle, O'Halloran Martin, O'Donnell Martin J

СтатьяМетаанализСистематический обзорПеревод пока не подготовлен

Аннотация

BACKGROUND

The association of lipid lowering therapy and intracerebral hemorrhage risk is controversial.

METHODS

We performed a cumulative meta-analysis of lipid lowering trials that reported intracerebral hemorrhage. Statin, fibrate, ezetimibe, PCSK9, and CETP trials were included. We explored whether the association of lipid lowering therapy and risk of intracerebral hemorrhage may vary by baseline low-density lipoprotein (LDL) level, mean change in LDL or baseline cardiovascular risk of population.

RESULTS

Among 39 trials (287,651 participants), lipid lowering therapy was not associated with a statistically significant increased risk of intracerebral hemorrhage (ICH) in primary and secondary prevention trials combined (odds ratio [OR], 1.12; 95% confidence interval [CI], .98-1.28). Lipid lowering was associated with an increased risk of ICH in secondary prevention trials (OR, 1.18; 95% CI, 1.00-1.38), but not in primary prevention trials (OR, 1.01; 95% CI, .78-1.30), but the test for interaction was not significant (P for interaction = .31). Meta-regression of baseline LDL or difference in LDL reduction between active and control did not explain significant heterogeneity between studies for ICH risk. Of 1000 individuals treated for 1 year for secondary prevention, we estimated 9.17 (95% CI, 5.78-12.66) fewer ischemic strokes and .48 (95% CI, .06-1.02) more ICH, and a net reduction of 8.69 in all stroke per 1000 person-years.

CONCLUSIONS

The benefits of lipid lowering therapy in prevention of ischemic stroke greatly exceed the risk of ICH. Concern about ICH should not discourage stroke clinicians from prescribing lipid lowering therapy for secondary prevention of ischemic stroke.

Для цитирования: Judge Conor, Ruttledge Sarah, Costello Maria, Murphy Robert, Loughlin Elaine, Alvarez-Iglesias Alberto, Ferguson John, Gorey Sarah, Nolan Aoife, Canavan Michelle, O'Halloran Martin, O'Donnell Martin J. Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage - A Meta-Analysis.. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2019. DOI: 10.1016/j.jstrokecerebrovasdis.2019.02.018.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.